Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Drug 'slows skin cancer progress'

  • Comment

A new skin cancer drug could be very effective in prolonging the lives of half of patients suffering from the disease, a study has revealed.

A trial of 680 patients at London’s Royal Marsden Hospital revealed that RG7204 was effective in slowing the spread of advanced malignant melanoma.

The drug locates and blocks genetic mutation found in half of all melanoma cases - the faulty BRAF protein. The drug was effective in shrinking tumours in 70% of cases.

Although researchers have not revealed how much longer patients taking the new drug lived, they confirmed that it was significantly longer than those receiving standard chemotherapy.

Dr Lesley Walker from Cancer Research UK said: “There are very few options for patients with advanced melanoma, so these results are really encouraging.

“The drug is not yet licensed and unavailable to patients not on a clinical trial, but we hope that these results will change this situation very rapidly.”

The study has not yet been fully published for review by other cancer specialists.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.